1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Neuromodulation Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Technology
6.1 Internal Neuromodulation
6.1.1 Market Trends
6.1.2 Key Segments
6.1.2.1 Spinal Cord Stimulation (SCS)
6.1.2.2 Deep Brain Stimulation (DBS)
6.1.2.3 Vagus Nerve Stimulation (VNS)
6.1.2.4 Sacral Nerve Stimulation (SNS)
6.1.2.5 Gastric Electrical Stimulation (GES)
6.1.3 Market Forecast
6.2 External Neuromodulation
6.2.1 Market Trends
6.2.2 Key Segments
6.2.2.1 Transcutaneous Electrical Nerve Stimulation (TENS)
6.2.2.2 Transcranial Magnetic Stimulation (TMS)
6.2.2.3 Others
6.2.3 Market Forecast
7 Market Breakup by Biomaterial
7.1 Metallic Biomaterials
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Polymeric Biomaterials
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Ceramic Biomaterials
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Application
8.1 Parkinson’s Disease
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Epilepsy
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Depression
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Dystonia
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Pain Management
8.5.1 Market Trends
8.5.2 Market Forecast
8.6 Others
8.6.1 Market Trends
8.6.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Abbott Laboratories
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Bioventus Inc.
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.3 Boston Scientific Corporation
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Helius Medical Technologies
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.5 Integer Holdings Corporation
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.6 LivaNova PLC
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.7 Medtronic plc
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 MicroTransponder Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.9 Neuronetics
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.10 NeuroPace Inc.
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.11 NeuroSigma Inc.
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.12 Nevro Corp.
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
14.3.12.3 Financials
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer